Everything in this article is accurate, regardless

Quote:

---

Everything in this article is accurate, regardless of their slant.

---

Not quite.

Quote:

---

CytoDyn's lead therapy is PRO 140 in treatment of HIV, which it claims to have blockbuster potential.

---

Yes, Cytodyn does claim that, because it's true. Has this author never taken at look at the clinical results?

Quote:

---

Instead of focusing all its efforts in a balls to the wall effort to secure FDA approval and then commercialize PRO 140, it's pursuing a variety of other indications for PRO 140.

---

The only non-HIV indication it's actively pursuing is mTNBC and great results from that alone can turn around the stock price.

ps. Either he reads ihub or posts there.

Quote:

---

CytoDyn has $0 revenue (p.27) and growing expenses (p. 4): Until it can start generating significant revenues from somewhere, it is entirely dependent on its ability to raise capital in order to continue its operations. Per its Q3 2019 10-Q (p. 27), CytoDyn expects no product revenue until the FDA approval of PRO 140.

---

When oh when will Cytodyn ever generate revenue. Does he think we're in Phase I?

Quote:

---

it is ill prepared for traversing the danger zone between FDA approval of PRO 140 and market acceptance of its new product.

---

Of course the market will ignore the only HIV drug that doesn't develop resistance.

Quote:

---

I am/we are long CYDY,

---

"I thought the company sucked in my last article and I bought it and still think it sucks, now sell me your shares cheap."